Erudio Healtherudio.com
Indication
Mantle cell lymphoma trials: what clinicians said in public
No HCP commentary report on a trial in mantle cell lymphoma yet. Erudio has found public clinician commentary on 13 clinical trials in mantle cell lymphoma, including BRUIN, EA4151, SYMPATICO and TRANSCEND NHL 001. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| SYMPATICO NCT03112174 · Pharmacyclics LLC. DeepView → | relapsed or refractory mantle cell lymphoma | Phase 3 | Deep | View | |||
| TRANSCEND NHL 001 NCT02631044 · Juno Therapeutics, a Subsidiary of Celgene DeepView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1 | Deep | View | |||
| EA4151 NCT03267433 · ECOG-ACRIN Cancer Research Group DeepView → | Not given | Phase 3 | Deep | View | |||
| BRUIN NCT03740529 · Loxo Oncology, Inc. DeepView → | previously treated CLL/SLL or non-Hodgkin lymphoma | Phase 1/Phase 2 | Deep | View | |||
| CaDAnCe-101 NCT05006716 · BeOne Medicines DeepView → | B-cell malignancies | Phase 1/Phase 2 | Deep | View | |||
| EA4181 NCT04115631 · ECOG-ACRIN Cancer Research Group StandardView → | untreated mantle cell lymphoma | Phase 2 | Standard | View | |||
| AIM NCT02471391 · Peter MacCallum Cancer Centre, Australia StandardView → | relapsed or refractory mantle cell lymphoma | Phase 2 | Standard | View | |||
| BMT CTN 1101 NCT01597778 · Medical College of Wisconsin StandardView → | hematologic malignancies | Phase 3 | Standard | View | |||
| CLOVER-1 NCT02952508 · Cellectar Biosciences, Inc. FocusedView → | relapsed or refractory B-cell malignancies | Phase 2 | Focused | View | |||
| NCT01776840 NCT01776840 · Janssen Research & Development, LLC FocusedView → | newly diagnosed mantle cell lymphoma | Phase 3 | Focused | View | |||
| OAsIs NCT02558816 · Nantes University Hospital FocusedView → | relapsed/refractory mantle cell lymphoma | Phase 1/Phase 2 | Focused | View | |||
| MK-1026-001 NCT03162536 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) FocusedView → | relapsed or refractory hematologic malignancies | Phase 1/Phase 2 | Focused | View | |||
| GLOASIS NCT06558604 · The Lymphoma Academic Research Organisation FocusedView → | high-risk mantle-cell lymphoma | Phase 2 | Focused | View | |||